Zhong Guo Jing Ji Wang·2024-12-12 03:07Core Viewpoint - Nanmo Bio (688265.SH) announced a share reduction plan by its major shareholder, Beijing Kangjun Ningyuan Equity Investment Partnership, due to funding needs, intending to reduce up to 1,481,306 shares, representing 1.90% of the total share capital [1][2]. Group 1: Shareholder Reduction Plan - The reduction period is set for three months starting from 15 trading days after the announcement [2]. - Kangjun Ningyuan currently holds 5,234,977 shares, accounting for 6.71% of Nanmo Bio's total share capital [2]. - The reduction will occur through centralized bidding and block trading, with a maximum of 701,671 shares through centralized bidding and 1,481,306 shares through block trading [1]. Group 2: Company Background - Nanmo Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial issuance of 19.49 million shares at a price of 84.62 yuan per share [3]. - The company raised a total of 1.649 billion yuan from its initial public offering, with a net amount of 1.468 billion yuan after deducting issuance costs [6][8]. - The final net fundraising amount exceeded the original plan by 1.068 billion yuan, with the initial target set at 400 million yuan for various projects [7]. Group 3: Current Stock Performance - Nanmo Bio's stock is currently in a state of decline, having opened below the issue price on its first trading day [4][5].